English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We aimed to determine the safety, immunogenicity and efficiency of an inactivated equine rotavirus vaccine. The vaccine was prepared with G3 serotype equine rotavirus. A dose of 2 ml was inoculated twice with a 1-month interval into the cervical muscles of 60 pregnant mares (40 on farm T and 20 on farm M). The first vaccination was conducted 2 or 3 months before full term. No abnormal signs were observed in the whole body or the inoculated area in any of the mares vaccinated. Serum neutralization antibody rose in 56 (93.3%) of the 60 vaccinated mares. The 60 foals born to the vaccinated mares possessed neutralization antibody titers of 1:320 to 1:10240. Sixteen foals on farm T developed diarrhea caused by serotype G14 rotavirus infection, but no foals on farm M developed diarrhea. Diarrhea in the foals born to vaccinated mares was a slight illness in comparison with that in foals born to unvaccinated mares. The vaccine is safe and immunogenic for pregnant mares, and vaccine-induced maternal antibody in the foals can reduce the signs of diarrhea caused by rotavirus infection.

Field Study of Inactivated Equine Rotavirus Vaccine